Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Deichmann, Martin ^a   Thome, Marianne ^a   Benner, Axel ^b   Kirschner, Martin ^a   Hassanzadeh, Judith ^a   Kurzen, Hjalmar ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; B RAF KINASE; GLUTAMIC ACID; GLYCINE; LYSINE; THREONINE; VALINE; PARAFFIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMPLICON; ARTICLE; CANCER RISK; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; EXON; FOLLOW UP; GEL ELECTROPHORESIS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOMA; METASTASIS; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTION; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN TUMOR; SOMATIC MUTATION; SUBCUTANEOUS TISSUE TUMOR; TISSUE SECTION; CHEMISTRY; DNA SEQUENCE; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PLASMID; POINT MUTATION; PROTEIN TERTIARY STRUCTURE; RISK; SIGNAL TRANSDUCTION; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

CELL DIFFERENTIATION; CELL PROLIFERATION; EXONS; HUMANS; MELANOCYTES; MELANOMA; MODELS, STATISTICAL; MUTATION; NEOPLASM METASTASIS; PARAFFIN; PLASMIDS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS B-RAF; RISK; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 26844479503     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-58     Document Type: Article

References (45)

1. Brochez L, Naeyaert JM: Understanding the trends in melanoma incidence and mortality, where do we stand? Eur. J. Dermatol. 2000, 10: 71-75
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davies N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949-954
3. Deichmann M, Thome M, Benner A, Egner U, Hartschuh W, Näher H: PTEN/MMAC1 expression in melanoma resection specimens. Br. J. Cancer 2002, 87: 1431-1436
4. Satyamoorthy K, Li G, Gerreo MR, Brose MS, Volpe P, Weber BL, van Belle P, Elder DE, Herlyn M: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003, 63: 756-759
5. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS: High frequency of BRAF mutations in nevi. Nat. Genet. 2003, 33: 19-20
6. Deichmann M, Thome M, Benner A, Näher H: B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology, 2004, in press
7. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D: Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003, 63: 3955-3957
8. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62: 6997-7000
9. Ruiz A, Antinolo G, Borrego S, Sánchez B, Sánchez J: PCR mutagenesis-based method for generation of positive controls for SSCP analysis. BioTechniques 1997, 3: 704-708
10. Hothorn T: On exact rank tests in R. R News 2001, 1: 11-12
11. R Development Core Team: R, a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2003
12. Daya-Grosjean L, Dumaz N, Sarasin A: The specificity of p53 mutation spectra in sunlight induced human cancers. J. Photochem. Photobiol. 1995, 28: 115-124
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene, clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54: 4855-4878
14. Moles UP, Moyret C, Guillot B, Jeanteur P, Guilhou JJ, Theillet C, Basset-Seguin N: p53 gene mutations in human epithelial skin cancers. Oncogene 1993, 8: 583-588
15. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE: Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc. Natl. Acad. Sci. U.S.A. 1993, 90: 4216-4220
16. Peyssonnaux C, Eychène A: The Raf/MEK/ERK pathway, new concepts of activation. Biol. Cell 2001, 93: 53-62
17. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA: Essential role for oncogenic Ras in tumor maintenance. Nature 1999, 400: 468-472
18. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U: N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol. 1998, 111: 757-761
19. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol. 1996, 149: 739-744
20. Kraehn GM, Schartl M, Peter RU: Human malignant melanoma, a genetic disease? Cancer 1995, 75: 1228-1237
21. van't Veer LJ, Burgering BMT, Versteeg R, Boot AJM, Ruiter DJ, Osanto S, Schrier PI, Bos JL: N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol. 1989, 9: 3114-3116
22. Wagner SN, Ockenfels HM, Wagner C, Hofler H, Goos M: Ras gene mutations, a rare event in nonmetastatic primary malignant melanoma. J. Invest. Dermatol. 1995, 104: 868-871
23. Barnier JV, Papin C, Eychène A, Lecoq O, Calothy G: The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J. Biol. Chem. 1995, 270: 23381-23389
24. Eychène A, Barnier JV, Dezelee P, Marx M, Laugier D, Calogeraki I, Calothy G: Quail neuroretina c-Rmil (B-raf) proto-oncogene cDNAs encode two proteins of 93.5 and 95 kDa resulting from alternative splicing. Oncogene 1992, 7: 1315-1323
25. Marx M, Eychène A, Laugier D, Bechade C, Crisanti P, Dezelee P, Pessac B, Calothy G: A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus. EMBO J. 1988, 11: 3369-3373
26. V599E as a melanoma cusceptibility mutation. Int. J. Cancer 2003, 106: 78-80
27. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Peer J, Sidransky D: Lack of BRAF mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44: 2876-2878
28. Edmunds SC, Cree IA, Nícolantonío FD, Hungerford JL, Hurren JS, Kelsell DP: Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer 2003, 88: 1403-1405
29. Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B: BRAF as a melanoma susceptibility candidate gene? Cancer Res. 2003, 63: 3061-3065
30. Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS: High frequency of BRAF mutations in nevi. Nature Genetics 2003, 33: 19-20
31. Mercer KE and Pritchard CA: Raf proteins and cancer, B-Raf is identified as a mutational target. Biochimica et Biophysica Acta 2003, 1653: 25-40
32. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaroson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003, 63: 3883-3885
33. Halaban R: The regulation of normal melanocyte proliferation. Pigment Cell Res. 2000, 13: 4-14
34. Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, Ortonne JP, Ballotti R: Ras mediates the cDMAP-dependent activation of extracellular signal-related kinases (ERKs) in melanocytes. EMBO J. 2000, 19: 2900-2910
35. Englaro W, Rezzonico R, Durand-Clément M, Lallemand D, Ortonne JP, Ballotti R: Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J. Biol. Chem. 1995, 270: 24315-24320
36. Imokawa G, Yada Y, Miyagishi M: Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J. Biol. Chem. 1992, 267: 24675-24680
37. Yada Y, Higuchi K, Imokawa G: Effects of endothelins on signal transduction and proliferation in human melanocytes. J. Biol. Chem. 1991, 266: 18352-18357
38. Imokawa G, Yada Y, Kimura M: Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem. J. 1996, 314: 305-312
39. Swope VB, Medrano EE, Smalara D, Abdel-Malek ZA: Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp. Cell Res. 1995, 217: 453-459
40. Imokawa G, Kobayasi T, Miyagishi M: Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes, cross-talk via trans-activation of the tyrosine kinase c-kit receptor. J. Biol. Chem. 2000, 275: 33321-33328
41. Cohen Y, Xing M, Mambo E, Guo Z, Wu Z, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D: BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 2003, 95: 625-627
42. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer, genetic evidence for constitutive activation of the RET/PCR-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63: 1454-1457
43. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273: 18623-18632
44. Kelemen BR, Hsiao K, Goueli SA: Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J. Biol. Chem. 2002, 277: 8741-8748
45. Tuveson DA, Weber BL, Herlyn M: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003, 4: 95-98